Table 6.
Baseline predictors factors of spine or pelvis structural lesions at T24.
| Spine structural lesions (presence = 1; absence = 0) | ||||
|---|---|---|---|---|
| Independent variables | Univariable analysis | Multivariable analysis | ||
| OR (IC) | p | coeff (IC) | p | |
| Female sex | 0.93 (0.69, 1.26) | 0.661 | – | – |
| LBP onset age | 0.90 (0.84, 0.97) | 0.006 | 0.89 (0.82, 0.97) | 0.010 |
| Duration of LBP | 0.97 (0.90, 1.05) | 0.495 | – | – |
| HLA-B27+ | 1.22 (0.48, 3.08) | 0.672 | – | – |
| Increased ESR/CRP | 0.46 (0.16, 1.31) | 0.147 | 0.57 (0.16, 1.93) | 0.369 |
| BASDAI > = 4 | 2.15 (0.79, 5.85) | 0.131 | 4.05 (1.15, 14.24) | 0.029 |
| Use of NSAIDs | 0.07 (0.008, 0.65) | 0.019 | 0.09 (0.008, 0.99) | 0.049 |
| SPARCC SIJ >2 | 1.28 (0.59, 2.44) | 0.531 | – | – |
| Pelvis structural lesions (presence = 1; absence = 0) | ||||
| Independent variables | Univariable analysis | Multivariable analysis | ||
| OR (IC) | p | coeff (IC) | p | |
| Female sex | 0.45 (0.17, 1.18) | 0.107 | 0.65 (0.21, 2.01) | 0.462 |
| LBP onset age | 0.98 (0.92, 1.03) | 0.527 | – | – |
| Duration of LBP | 1.00 (0.92, 1.08) | 0.951 | – | – |
| HLA-B27+ | 1.45 (0.58, 3.60) | 0.423 | – | – |
| Increased ESR/CRP | 1.27 (0.48, 3.35) | 0.629 | – | – |
| BASDAI > = 4 | 0.43 (0.16, 1.14) | 0.091 | 0.60 (0.19, 1.84) | 0.375 |
| Use of NSAIDs | 1.77 (0.32, 9.84) | 0.511 | – | – |
| SPARCC SIJ >2 | 1.07 (1.026, 1.13) | 0.003 | 1.07 (1.01, 1.12) | 0.007 |
LBP, low back pain; HLA-B27, human leukocyte antigen B27; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; BASDAI, bath ankylosing spondylitis disease activity index; NSAIDs, non-steroidal antiinflammatory drugs; SPARCC, spondyloarthritis research consortium of Canada; SIJ, sacroiliac joints; T24, 24 months; OR, Odds Ratio.